Sentence examples for indications demonstrate from inspiring English sources

All indications demonstrate that the Khamenei clique is far more interested in maintaining their political dominance of Iran than improving the economy.

Although agreement exists regarding the use of corticosteroids for refractory hypotension, other indications demonstrated poor to modest guideline concordance.

Analysis of adverse events of interest through nearly 12 years of adalimumab exposure in clinical trials across indications demonstrated individual differences in rates by disease populations, no new safety signals and a safety profile consistent with known information about the anti-TNF class.

Preliminary indications demonstrated that marked AF signals and photolability are exhibited by fatty acids such as arachidonic, linoleic, and stearic acids, while other derivatives such as butirric and palmitic acids, triglycerides, and phospholipids are in general poorly fluorescent ([ 22, 24, 47] and unpublished results).

In some cases, however, there may be clinical indications to demonstrate vasovagal tendencies to the patient by performing tilt-table tests.

Before starting the trial, several meetings were organised among participating centres to explain the terminology, to debate the proper indications and demonstrate the surgical technique.

In other words, the two drugs appeared to be used for similar indications and demonstrated similar clinical usage patterns.

As for laboratory tests, a computerized radiology order entry system with decision support based on clinical reasoning strategies and utility scores on the indications was demonstrated to have an important impact on physicians' ordering practices [ 35].

Under such schemes, the price of a drug would be based on the value it adds in each individual indication, as demonstrated through technology appraisals [ 5].

Immunotherapeutic agents are more successful, and studies with recombinant human interleukin-2 (rIL-2), the first cytokine registered for this indication, have demonstrated survival benefits over chemotherapy for the majority of patients with mRCC (Jones et al, 1993; Bordin et al, 2000; Fisher et al, 2000; Atzpodien et al, 2002; Lissoni et al, 2002; Pantuck et al, 2002).

Romidepsin is a potent, class 1 selective histone deacetylase (HDAC) inhibitor 1– 3 approved by the US Food and Drug Administration FDAA) for the treatment of patients with cutaneous or peripheral T-cell lymphoma (CTCL, PTCL) who received ≥1 prior systemic therapy 4. Approvals were based primarily on pivotal phase 2 studies in each indication, which demonstrated durable single-agent activity 5, 6.